What GLP-1 Medications Like Ozempic May Be Doing to Your Voice

GLP-1s, the class of medications that includes semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro), have become among the most prescribed drugs in the United States. Roughly one in eight American adults has taken a GLP-1 medication at some point (Saleem et al., 2025). Their benefits for weight management and metabolic health are well documented. What is less discussed is how the known side effect profile of these medications interacts with the larynx and vocal tract. 

The Dehydration Mechanism

The most direct vocal consequence of GLP-1 medications comes through their effect on hydration. These drugs work in part by slowing gastric emptying and suppressing appetite, which may cause nausea, vomiting, and diarrhea. Each of these side effects represents a risk of fluid loss (Zhou et al., 2024).

As established in the vocal science literature, even mild dehydration increases the minimum effort required to initiate and sustain vocal fold vibration (Jiang et al., 2000). A performer on GLP-1 therapy may drink and eat less than usual, thereby performing in a chronic low-grade dehydration state without recognizing it as the source of their vocal fatigue or reduced range.

 The Reflux Connection

GLP-1 medications slow gastric emptying, which means food and acid remain in the stomach longer than usual. For individuals already prone to gastroesophageal reflux or laryngopharyngeal reflux (LPR), this can worsen reflux significantly. LPR, in which stomach acid reaches the larynx and vocal folds without producing classic heartburn symptoms, may cause hoarseness, loss of range, and vocal fatigue in professional voice users.

A performer who develops new or worsening hoarseness after starting a GLP-1 medication may be experiencing a medication-related reflux component.

Hoarseness as a Warning Sign

The FDA flags hoarseness as a symptom warranting immediate medical attention, specifically in the context of potential thyroid C-cell tumor risk (Novo Nordisk, 2026). While the clinical evidence for semaglutide causing thyroid tumors in humans remains inconclusive, the inclusion of hoarseness as a reportable symptom underscores that any new vocal change in a patient on GLP-1 therapy should be evaluated by a physician, not attributed to routine vocal use.

For professional voice users, the threshold for evaluation should be lower still. Unexplained hoarseness lasting more than two to three days, new vocal fatigue, or a change in range or quality that coincides with starting or increasing a GLP-1 medication should be a trigger to schedule a laryngological evaluation.

Muscle Loss and Breath Support

One of the more significant concerns emerging around long-term GLP-1 use is the accompanying loss of lean muscle mass alongside fat tissue. A clinical trial currently underway at the University of Wisconsin is specifically investigating changes in skeletal and cardiac muscle mass over twelve months of semaglutide use (ClinicalTrials.gov, NCT07272837, 2026).

For voice professionals, respiratory muscle integrity is central to vocal function. The intercostal and abdominal muscles are the engine of breath support. A progressive reduction in lean muscle mass, particularly in patients who are not following a resistance training protocol alongside GLP-1 therapy, could gradually compromise the breath support that powers the voice. Strength training, with specific attention to core strengthening, can reduce this risk.

Practical Guidance for Voice Professionals on GLP-1 Medications

None of the above is an argument against GLP-1 therapy for patients for whom it is clinically appropriate. It is an argument for active vocal monitoring and a few specific management strategies.

Hydration should be a deliberate priority. If nausea, vomiting, or diarrhea occur, fluid and electrolyte replacement should be prioritized.

Reflux management strategies, including dietary trigger avoidance and meal timing adjustments are worth implementing rather than waiting for vocal symptoms to develop. If reflux symptoms do emerge, discussion with a physician about appropriate medical management alongside the GLP-1 medication is appropriate.

Resistance training, where medically appropriate, can help preserve the lean muscle mass that supports respiratory function. This is an area where coordination between a prescribing physician and a vocal health specialist is genuinely useful.

Finally, a baseline laryngoscopic evaluation before starting GLP-1 therapy, and a follow-up if new vocal symptoms develop, gives both patient and clinician a reference point for assessing change. At the Center for Vocal Health, we offer this kind of proactive vocal monitoring for patients navigating significant medical or pharmaceutical changes.

References

Saleem, N. U. A., Khan, M., Tague, C., & Akilimali, A. (2025). The unseen risk of Ozempic: NAION and vision damage. Annals of Medicine & Surgery, 88(1). NihThe unseen risk of Ozempic: NAION and vision damage

Zhou, Y., et al. (2024). Pharmacovigilance study of GLP-1 receptor agonists for metabolic disorders: Focus on dehydration risks. Frontiers in Pharmacology, 15, Article 1416985. https://www.frontiersin.org/articles/10.3389/fphar.2024.1416985/fu

Jiang, J., Verdolini, K., Aquino, B., Ng, J., & Hanson, D. (2000). Effects of dehydration on phonation in excised canine larynges. Annals of Otology, Rhinology & Laryngology, 109(6), 568–575. NihEffects of dehydration on phonation in excised canine larynges - PubMed

Novo Nordisk. (2026, January). Ozempic (semaglutide) prescribing information. DailyMed. NihDailyMed - OZEMPIC- oral semaglutide tablet RYBELSUS- oral semaglutide tablet

ClinicalTrials.gov. (2026). Impact of semaglutide (Ozempic/Wegovy) on heart and muscle mass (NCT07272837). U.S. National Library of Medicine. ClinicaltrialsClinicalTrials.gov